Edition:
United States

UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

63.30EUR
20 Jan 2017
Change (% chg)

€-0.28 (-0.44%)
Prev Close
€63.58
Open
€63.68
Day's High
€63.86
Day's Low
€62.70
Volume
416,371
Avg. Vol
308,343
52-wk High
€85.12
52-wk Low
€54.84

Select another date:

Thu, Jan 19 2017

BRIEF-UCB files Briviact CV in US as monotherapy treatment for adult epilepsy patients with partial-onset seizures

* UCB files Briviact (brivaracetam) CV in the US as monotherapy treatment for adult epilepsy patients with partial-onset seizures Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-UCB: CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trials

* CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trials

BRIEF-UCB says head-to-head study of Cimzia and Humira did not meet primary endpoints

* The Lancet publishes first head-to-head study of Cimzia (certolizumab pegol) and Humira (adalimumab) in bio-naïve rheumatoid arthritis patients

BRIEF-UCB gives results from phase 3 bridge study

* Results from phase 3 Bridge study showed romosozumab significantly increased bone mineral density in men with osteoporosis

BRIEF-UCB's anti-epileptic drug VIMPAT receives positive opinion by EU CHMP

* UCB's anti-epileptic drug VIMPAT (lacosamide) receives positive opinion by EU CHMP as monotherapy for patients with partial-onset seizures Source text: http://bit.ly/2fIeuV8 Further company coverage: (Gdynia Newsroom)

Belgium's UCB guides for upper end of 2016 forecast range

BRUSSELS, Oct 25 Belgian pharma group UCB on Tuesday said its 2016 results should come in at the upper end of its guidance range, as its main products sold strongly in the first nine months of the year.

BRIEF-UCB Q3 revenue up 7 pct, 2016 guidance confirmed

* Reports 9 month revenue of 3.08 billion euros ($3.35 billion) versus 2.86 billion euros year ago

BRIEF-UCB CIMZIA Phase 3 trial meets co-primary efficacy endpoints

* CIMZIA (certolizumab pegol) Phase 3 trial meets co-primary efficacy endpoints in patients with moderate-to-severe chronic plaque psoriasis

BRIEF-Amgen and UCB say FDA accepts biologics license application for romosozumab

* Amgen and UCB announce FDA acceptance of biologics license application for romosozumab

BRIEF-UCB receives positive EU CHMP opinion for Cimzia

* Receives positive EU CHMP opinion for Cimzia (certolizumab pegol) autoclicks Prefilled Pen Source text: http://bit.ly/2cWGynH Further company coverage: (Gdynia Newsroom)

Select another date: